Palatin Technologies Inc.

ASE:PTN  
0.51
+0.02 (+5.16%)
4:43:38 PM EDT: $0.53 +0.02 (+3.94%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)122.73M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.7 Million
Adjusted EPS-$0.03
See more estimates
10-Day MA$0.54
50-Day MA$0.65
200-Day MA$0.61
See more pivots

Palatin Technologies Inc. Stock, ASE:PTN

Cedar Brook Corporate Center, 4-B Cedar Brook Drive, Cranbury, New Jersey 08512
United States of America
Phone: +1.609.495.2200
Number of Employees: 20

Description

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.